Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 14 , ISSUE 2 ( July-December, 2024 ) > List of Articles

Original Article

Higher Incidence of Diabetes in Asymptomatic Healthy Fatty Liver Patients of Bangladesh: Prompt Intervention can Avert Complications

ABM Shakil Gani, Abdullah Al Mahmood, AFM Shafiqul Alam, Mizanur Rahman, Raqibul Alam, Tasnim Mahmud

Keywords : Fatty liver, Metabolic dysfunction-associated steatotic liver disease, Steatohepatitis, Type 2 diabetes mellitus

Citation Information : Gani AS, Mahmood AA, Alam AS, Rahman M, Alam R, Mahmud T. Higher Incidence of Diabetes in Asymptomatic Healthy Fatty Liver Patients of Bangladesh: Prompt Intervention can Avert Complications. Euroasian J Hepatogastroenterol 2024; 14 (2):172-175.

DOI: 10.5005/jp-journals-10018-1444

License: CC BY-NC 4.0

Published Online: 27-12-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Background: The strong association between type 2 diabetes mellitus (T2DM) and fatty liver is well known, and its nomenclature has even recently changed to metabolic dysfunction-associated steatotic liver disease (MASLD). Healthy MASLD patients are frequently overlooked and maltreated, especially in Bangladesh. In this present study, we tried to correlate T2DM burden in apparently healthy, incidentally diagnosed fatty liver patients on ultrasound. Materials and methods: This cross-sectional study was done in Sheikh Hasina Medical College Hospital, Tangail, Bangladesh, from August 2022 to February 2023. A total of 92 patients with ultrasonological evidence of grade II fatty change in the liver were included and evaluated. Known T2DM, hypothyroidism, consumption of alcohol, HBV or HCV infection, Wilson's disease, autoimmune liver disease, hemochromatosis, and any other chronic liver or kidney disease patients were excluded. The patients were then assessed for the presence and absence of T2DM using OGTT (2 hours 75 gm glucose ≥ 11.1 mmol/L) and/or HbA1c (≥6.5%) as diagnostic criteria. Data was analyzed by SPSS, version 23. Results: Out of 92 patients, 48 were male and 44 were female. A total of 50 patients (54.3%) were newly diagnosed with T2DM. Statistically significant differences were seen in the T2DM group and non-DM group for AST (50.33 IU vs 36.53 IU) and TG (270 mg/dL vs 189 mg/dL). Although no noteworthy differences were evident in mean age (41 years vs 38 years), ALT (58.9 IU vs 60.23 IU), and BMI (28.85 vs 29.29). Conclusions: In the present study, more than 54% of patients with grade II fatty liver were newly diagnosed with T2DM. They would later present with more advanced T2DM and related complications. Although a larger study is needed, physicians and healthcare workers in Bangladesh should be more concerned about treating MASLD patients with early diagnosis of T2DM, recommending prompt lifestyle interventions, and prescribing drugs if necessary.


PDF Share
  1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4–14. DOI: 10.1016/j.diabres.2009.10.007.
  2. Jayawardena R, Ranasinghe P, Byrne NM, et al. Prevalence and trends of the diabetes epidemic in South Asia: A systematic review and meta-analysis. BMC Public Health 2012;12:380. DOI: 10.1186/1471-2458-12-380.
  3. Hu FB. Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care 2011;34:124957. DOI:10.2337/dc110442.
  4. Padda J, Khalid K, Khedr A, et al. Non-alcoholic fatty liver disease and its association with diabetes mellitus. Cureus 2021;13(8):e17321. DOI: 10.7759/cureus.17321.
  5. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524–30. DOI: 10.1016/j.cgh.2011.03.020.
  6. Qiu S, Cai X, Sun Z, et al. Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis. Therap Adv Gastroenterol 2017;10:701–713. DOI: 10.1177/1756283X17725977.
  7. Dharmalingam M, Yamas PG. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian J Endocr Metab 2018;22:421–428. DOI: 10.4103/ijem.IJEM_585_17.
  8. Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol 2019:70(3):531–534. DOI: 10.1016/j.jhep.2018.10.033.
  9. Chowdhury MZI, Anik AM, Farhana Z, et al. Prevalence of metabolic syndrome in Bangladesh: A systematic review and meta-analysis of the studies. BMC Public Health 2018:18:308. DOI: 10.1186/s12889-018-5209-z.
  10. Ha J, Hang OK, Han K, et al. Metabolic dysfunction-associated fatty liver disease increases the risk of type 2 diabetes mellitus in young Korean adults. Diabetes Res Clin Pract 2024;212:11584. DOI: 10.1016/j.diabres.2024.111584.
  11. Islam RM, Khan MN, Oldroyd JC, et al. Prevalence of diabetes and prediabetes among Bangladeshi adults and associated factors: Evidence from the Demographic and Health Survey, 2017–18. medRxiv 2021.01.26.21250519. DOI: 10.1101/2021.01.26.21250519.
  12. Saquib N, Saquib J, Ahmed T, et al. Cardiovascular diseases and type 2 diabetes in Bangladesh: A systematic review and meta-analysis of studies between 1995 and 2010. BMC Public Health 2012;12:434. DOI: 10.1186/1471-2458-12-434.
  13. Karar ZA, Alam N, Streatfield PK. Epidemiological transition in rural Bangladesh, 1986–2006. Glob Health Action 2009;2:1904. DOI: 10.3402/gha.v2i0.1904.
  14. Laskar SI. Urbanization in Bangladesh: Some contemporary observations. Bangladesh Dev Stud 1996;24:207–216. PMID: 1234 6544.
  15. Misra A, Misra R, Wijesuriya M, et al. The metabolic syndrome in South Asians: Continuing escalation and possible solutions. Indian J Med Res 2007;125:345–354. PMID: 17496360.
  16. WHO. WHO Library Cataloguing-in-Publication Data Global report on diabetes. 2016.
  17. Akhtar S, Nasir JA, Sarwar A, et al. Prevalence of diabetes and pre-diabetes in Bangladesh: A systematic review and meta-analysis. BMJ Open 2020;10:e036086. DOI: 10.1136/bmjopen-2019-036086.
  18. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of abnormal liver chemistries. Am J Gastroenterol 2017;112(1):18. PMID 27995906.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.